Jump to content

BCKDK

From Wikipedia, the free encyclopedia
(Redirected from BCKDK (gene))

BCKDK
Identifiers
AliasesBCKDK, BCKDKD, BDK, branched chain ketoacid dehydrogenase kinase, branched chain keto acid dehydrogenase kinase
External IDsOMIM: 614901; MGI: 1276121; HomoloGene: 37642; GeneCards: BCKDK; OMA:BCKDK - orthologs
Orthologs
SpeciesHumanMouse
Entrez

10295

12041

Ensembl

ENSG00000103507

ENSMUSG00000030802

UniProt

O14874

O55028

RefSeq (mRNA)

NM_005881
NM_001122957
NM_001271926

NM_009739

RefSeq (protein)

NP_001116429
NP_001258855
NP_005872
NP_005872.2

NP_033869

Location (UCSC)Chr 16: 31.11 – 31.11 MbChr 7: 127.5 – 127.51 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Branched chain ketoacid dehydrogenase kinase (BCKDK) is an enzyme encoded by the BCKDK gene on chromosome 16. This enzyme is part of the mitochondrial protein kinases family and it is a regulator of the valine, leucine, and isoleucine catabolic pathways.[5] BCKDK is found in the mitochondrial matrix and the prevalence of it depends on the type of cell. Liver cells tend to have the lowest concentration of BCKDK, whereas skeletal muscle cells have the highest amount.[6][7] Abnormal activity of this enzyme often leads to diseases such as maple syrup urine disease and cachexia.

Structure

[edit]

BCKDK's structure consists of a characteristic nucleotide-binding domain along with a four-helix bundle domain similar to certain aspects of protein histidine kinases, which are involved in two-component signal transduction systems. BCKDK is also a dimer with a Leu389 residue located between the dimers and this dimerization is seen to be essential for its kinase activity and protein stability.[8] Moreover, it is made up of 382 amino acids and has a molecular weight of 43 kDa.[6] The gene BCKDK is located at 16p11.2, has an exon count of 11, and it lacks a TATA-box and an initiator element.[5][7]

Function

[edit]

BCKDK regulates the activity of branched-chain α-ketoacid dehydrogenase complex (BCKD) through phosphorylation and inactivation. This inactivation results in increased branched-chain amino acids (BCAA), which is seen to reduce oxidative stress; however, having too much BCAA has been proven to be toxic to humans. Therefore, BCKDK is a vital tool to assist with BCAA homeostasis.[9][10] As stated earlier, BCKDK concentrations vary depending on the type of tissue that is observed, whereas BCKD's concentration is the same in any tissue. Although BCKD concentration is constant, the amount of BCKDK determines the activity of the dehydrogenase complex. Since liver tissue is seen to have the lowest concentration of BCKDK, the activity of BCKD is seen to be the highest, delineating the fact that the BCKD kinase inversely affects the BCKD activity.[7]

Clinical significance

[edit]

Abnormalities in BCKD activity often leads to pathological conditions which is why BCKDK is needed to regulate it. Often, mutations in the BCKDK gene occur creating the deviation in BCKD behavior. Exceedingly high BCKD complex activity increases branched-chain amino acid catabolism and protein degradation in skeletal muscle, which is a distinctive feature for cachexia. Deficiencies in BCKD activity have been the main cause in the rare metabolism maple syrup urine disease that can lead to mental retardation, brain edema, seizures, coma, and death if not treated correctly by lifelong limitation of branched-chain amino acid intake.[7] Because BCKDK regulates BCKD which in turn catalyzes BCAA, BCKDK is one of the factors that determines the concentration of BCAA levels. High BCAA levels can lead to insulin resistance and can be a potential marker for type 2 diabetes.[10] The amalgamation of BCAA can also lead to congenital heart diseases and heart failure. Furthermore, low levels of BCAA have been described as a cause of comorbid intellectual disability, autism, and epilepsy.[8]

Deficiency of BCKDK, first described in 2012,[11] is a disorder that could be considered as the "opposite" of maple syrup disease, because patients have decreased levels of branched-chain amino acids, instead of increased levels. The condition may present as autism with epileptiform abnormalities on EEG and seizures.

Therapeutics development

[edit]

In 2023, Pfizer reported the development of the thiophene PF-07208254 as an allosteric BCKDK inhibitor that also promotes BCKDK degradation by promoting BCKDK interaction with BCKDH-E2.[12] A variant of this molecule, PF-07328948, was disclosed in 2024 and is being evaluated as a clinical candidate for heart failure.[13][14]

Interactions

[edit]

BCKDK has been seen to interact with:

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000103507 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000030802 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ a b "Entrez Gene: BCKDK branched chain ketoacid dehydrogenase kinase".
  6. ^ a b c Popov KM, Zhao Y, Shimomura Y, Kuntz MJ, Harris RA (Jul 1992). "Branched-chain alpha-ketoacid dehydrogenase kinase. Molecular cloning, expression, and sequence similarity with histidine protein kinases". The Journal of Biological Chemistry. 267 (19): 13127–30. doi:10.1016/S0021-9258(18)42179-5. PMID 1377677.
  7. ^ a b c d Muller EA, Danner DJ (Oct 2004). "Tissue-specific translation of murine branched-chain alpha-ketoacid dehydrogenase kinase mRNA is dependent upon an upstream open reading frame in the 5'-untranslated region". The Journal of Biological Chemistry. 279 (43): 44645–55. doi:10.1074/jbc.M406550200. PMID 15302860.
  8. ^ a b García-Cazorla A, Oyarzabal A, Fort J, Robles C, Castejón E, Ruiz-Sala P, Bodoy S, Merinero B, Lopez-Sala A, Dopazo J, Nunes V, Ugarte M, Artuch R, Palacín M, Rodríguez-Pombo P, Alcaide P, Navarrete R, Sanz P, Font-Llitjós M, Vilaseca MA, Ormaizabal A, Pristoupilova A, Agulló SB (Apr 2014). "Two novel mutations in the BCKDK (branched-chain keto-acid dehydrogenase kinase) gene are responsible for a neurobehavioral deficit in two pediatric unrelated patients". Human Mutation. 35 (4): 470–7. doi:10.1002/humu.22513. PMID 24449431. S2CID 205922143.
  9. ^ Tso SC, Gui WJ, Wu CY, Chuang JL, Qi X, Skvora KJ, Dork K, Wallace AL, Morlock LK, Lee BH, Hutson SM, Strom SC, Williams NS, Tambar UK, Wynn RM, Chuang DT (Jul 2014). "Benzothiophene carboxylate derivatives as novel allosteric inhibitors of branched-chain α-ketoacid dehydrogenase kinase". The Journal of Biological Chemistry. 289 (30): 20583–93. doi:10.1074/jbc.M114.569251. PMC 4110271. PMID 24895126.
  10. ^ a b Tso SC, Qi X, Gui WJ, Chuang JL, Morlock LK, Wallace AL, Ahmed K, Laxman S, Campeau PM, Lee BH, Hutson SM, Tu BP, Williams NS, Tambar UK, Wynn RM, Chuang DT (Jun 2013). "Structure-based design and mechanisms of allosteric inhibitors for mitochondrial branched-chain α-ketoacid dehydrogenase kinase". Proceedings of the National Academy of Sciences of the United States of America. 110 (24): 9728–33. Bibcode:2013PNAS..110.9728T. doi:10.1073/pnas.1303220110. PMC 3683707. PMID 23716694.
  11. ^ Novarino G, El-Fishawy P, Kayserili H, Meguid NA, Scott EM, Schroth J, Silhavy JL, Kara M, Khalil RO, Ben-Omran T, Ercan-Sencicek AG, Hashish AF, Sanders SJ, Gupta AR, Hashem HS, Matern D, Gabriel S, Sweetman L, Rahimi Y, Harris RA, State MW, Gleeson JG (October 2012). "Mutations in BCKD-kinase lead to a potentially treatable form of autism with epilepsy". Science. 338 (6105): 394–7. Bibcode:2012Sci...338..394N. doi:10.1126/science.1224631. PMC 3704165. PMID 22956686.
  12. ^ Roth Flach RJ, Bollinger E, Reyes AR, Laforest B, Kormos BL, Liu S, Reese MR, Martinez Alsina LA, Buzon L, Zhang Y, Bechle B, Rosado A, Sahasrabudhe PV, Knafels J, Bhattacharya SK (2023-08-09). "Small molecule branched-chain ketoacid dehydrogenase kinase (BDK) inhibitors with opposing effects on BDK protein levels". Nature Communications. 14 (1): 4812. doi:10.1038/s41467-023-40536-y. ISSN 2041-1723. PMC 10412597.
  13. ^ "ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2024-10-25.
  14. ^ "ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2024-10-25.

Further reading

[edit]
[edit]
Retrieved from "https://wiki.riteme.site/w/index.php?title=BCKDK&oldid=1255807199"